You are here

  • Home
  • Archive
  • Volume 72, Issue 11
  • The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab

Article info

Article menu
Download PDFPDF
Letters
The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab

Authors

  1. Correspondence to Dr Chamaida Plasencia, Rheumatology Department, La Paz University Hospital-Idipaz, Paseo la Castellana 261, Madrid PC 28046, Spain; chamiplasencia{at}hotmail.com
View Full Text

Citation

Plasencia C, Pascual-Salcedo D, Alcocer P, et al
The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab
Annals of the Rheumatic Diseases 2013;72:1888-1890.

Publication history

  • Accepted May 12, 2013
  • First published June 5, 2013.
Online issue publication 
October 03, 2013

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions